Emerging Therapeutic Opportunities in Prostate Cancer

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space.

Transcript

I think we’ve got some very interesting things going on within prostate cancer. And I bring that to our attention because here in specialty pharmacy we’ve got a lot of opportunities, right. So with prostate cancer, by the time we get to see these patients many times they’re castration-resistant. We begin to see more therapies that maybe don’t have as much of a CNS side effect. So these patients we often want to make sure they’re not having types of falls or anything like that, so we’ve got some developing going on there. I think, also, opportunities around specialty generics. So we should see abiraterone go generic at some point, maybe in the next few months or year, however we see that come down.